EyePoint Pharmaceuticals Statistics
Want to see EYPT full AI Analyst Report?
EyePoint Pharmaceuticals (EYPT) Stock Statistics & Valuation Metrics
Total Valuation
EyePoint Pharmaceuticals has a market cap or net worth of $34.82M. The enterprise value is $195.37M.
- Market Cap
- $34.82M
- Enterprise Value
- $195.37M
Share Statistics
EyePoint Pharmaceuticals has 113,782,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 113,782,600
- Owned by Insiders
- 7.94%
- Owned by Institutions
- 35.99%
Financial Efficiency
EyePoint Pharmaceuticals’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -73.99%.
- Return on Equity (ROE)
- -0.76
- Return on Assets (ROA)
- -0.64
- Return on Invested Capital (ROIC)
- -73.99%
- Return on Capital Employed (ROCE)
- -0.74
- Revenue Per Employee
- 146.59K
- Profits Per Employee
- -1.08M
- Employee Count
- 214
- Asset Turnover
- 0.09
- Inventory Turnover
- 1.14
Valuation Ratios
The current PE Ratio of EyePoint Pharmaceuticals is -0.08. EyePoint Pharmaceuticals’s PEG ratio is 0.00.
- PE Ratio
- -0.08
- PS Ratio
- 9.95
- PB Ratio
- 0.25
- Price to FCF
- -0.09
- Price to Operating Cash Flow
- -0.09
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, EyePoint Pharmaceuticals had revenue of 31.37M and earned -231.96M in profits. Earnings per share was -3.17.
- Revenue
- 31.37M
- Gross Profit
- 29.30M
- Operating Income
- -243.43M
- Pretax Income
- -231.68M
- Net Income
- -231.96M
- EBITDA
- -229.34M
- Earnings Per Share (EPS)
- -3.17
Cash Flow
In the last 12 months, operating cash flow was -294.76M and capital expenditures -4.39M, giving a free cash flow of -299.15M billion.
- Operating Cash Flow
- -294.76M
- Free Cash Flow
- -299.15M
- Free Cash Flow per Share
- -3.35
Dividends & Yields
EyePoint Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1166.03%
- Earnings Yield
- -1254.25%
Stock Price Statistics
- Beta
- 2.53
- 52-Week Price Change
- -97.34%
- 50-Day Moving Average
- 2.33
- 200-Day Moving Average
- 10.19
- Relative Strength Index (RSI)
- 18.08
- Average Volume (3m)
- 9.44M
Important Dates
EyePoint Pharmaceuticals upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
EyePoint Pharmaceuticals as a current ratio of 8.88, with Debt / Equity ratio of 7.45%
- Current Ratio
- 8.88
- Quick Ratio
- 8.83
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.34
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, EyePoint Pharmaceuticals has paid 279.00K in taxes.
- Income Tax
- 279.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
EyePoint Pharmaceuticals EV to EBITDA ratio is 0.12, with an EV/FCF ratio of 0.13.
- EV to Sales
- -14.90
- EV to EBITDA
- 0.12
- EV to Free Cash Flow
- 0.13
- EV to Operating Cash Flow
- 0.13
Balance Sheet
EyePoint Pharmaceuticals has $118.21M in cash and marketable securities with $19.12M in debt, giving a net cash position of $99.09M billion.
- Cash & Marketable Securities
- $118.21M
- Total Debt
- $19.12M
- Net Cash
- $99.09M
- Net Cash Per Share
- $0.87
- Tangible Book Value Per Share
- $1.22
Margins
Gross margin is 44.71%, with operating margin of -13642.03%, and net profit margin of -13281.23%.
- Gross Margin
- 44.71%
- Operating Margin
- -13642.03%
- Pretax Margin
- -13275.96%
- Net Profit Margin
- -13281.23%
- EBITDA Margin
- -12853.86%
- EBIT Margin
- -12932.34%
Analyst Forecast
The average price target for EyePoint Pharmaceuticals is $2.58, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- $2.58
- Price Target Upside
- 744.23% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 13
- Revenue Growth Forecast
- -93.91%
- EPS Growth Forecast
- -32.55%
Scores
- Smart Score
- 2
- AI Score
- 41

